13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000909661
Total reported value
$21.7B
$21.7B
172 檔
24.8%
According to the latest 13F quarterly dataset, Farallon Capital Management, L.l.c. managed an equity portfolio of $21.7B at the end of Q1 2026, spanning 172 distinct U.S. exchange-listed positions.
In Q1 2026, Farallon Capital Management, L.l.c. displayed an active expansion posture, initiating 172 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 8.53% | -8.53% | EXIT | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.54% | +4.17% | -6.71% | |
| 3 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 5.01% | -2.11% | -6.26% | |
| 4 | MSFT | Microsoft CORP | Stock-Tech | 4.95% | -3.03% | +5.90% | |
| 5 | AON | Aon plc | Stock-Financials | 4.62% | -2.50% | -5.73% | |
| 6 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.96% | -0.27% | +4.08% | |
| 7 | ✓ | Stock-Other | 3.94% | -3.94% | EXIT | ||
| 8 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.81% | -0.22% | +3.33% | |
| 9 | NTRA | Natera Inc | Stock-Healthcare | 3.66% | -0.88% | -18.06% | |
| 10 | EXEL | Exelixis Inc | Stock-Healthcare | 3.21% | +0.17% | -16.54% | |
| 11 | AVGO | Broadcom Inc | Stock-Tech | 3.14% | -1.13% | +99.41% | |
| 12 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.81% | -0.37% | +13.93% | |
| 13 | SNPS | Synopsys Inc | Stock-Tech | 2.74% | -1.03% | +21.43% | |
| 14 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.67% | -0.60% | +0.42% | |
| 15 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 2.47% | -0.04% | +38.67% | |
| 16 | KKR | Kkr & Co Inc | Stock-Financials | 2.46% | -0.72% | +131.54% | |
| 17 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 2.41% | +0.45% | +2.87% | |
| 18 | WAB | Wabtec CORP | Stock-Industrials | 2.29% | -1.18% | -35.00% | |
| 19 | SCHW | Schwab (charles) CORP | Stock-Financials | 2.12% | -2.12% | EXIT | |
| 20 | LQDA | Liquidia CORP | Stock-Other | 1.86% | +1.22% | — | |
| 21 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.73% | -0.18% | +20.27% | |
| 22 | GOOG | Alphabet Inc-cl C | Stock-Comm Services | 1.63% | -1.63% | EXIT | |
| 23 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 1.53% | +0.81% | +26048.65% | |
| 24 | V | Visa Inc-class A Shares | Stock-Financials | 1.45% | -1.45% | EXIT | |
| 25 | ARMK | Aramark | Stock-Industrials | 1.42% | -0.47% | -34.43% | |
| 26 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.38% | +0.24% | +0.71% | |
| 27 | DIS | Walt Disney Co/the | Stock-Comm Services | 1.32% | -1.32% | EXIT | |
| 28 | MA | Mastercard Inc - A | Stock-Financials | 1.24% | -1.24% | EXIT | |
| 29 | MCK | Mckesson CORP | Stock-Healthcare | 1.16% | -1.16% | EXIT | |
| 30 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.10% | -0.09% | +10.17% | |
| 31 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.09% | -1.09% | EXIT | |
| 32 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.08% | +0.69% | -30.35% | |
| 33 | GRAL | Grail Inc | Stock-Healthcare | 0.96% | +0.35% | +38.89% | |
| 34 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.78% | -0.78% | EXIT | |
| 35 | THC | Tenet Healthcare CORP | Stock-Healthcare | 0.49% | -0.49% | EXIT | |
| 36 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.44% | -0.44% | EXIT | |
| 37 | PCVX | Vaxcyte Inc | Stock-Other | 0.42% | -0.42% | EXIT | |
| 38 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.40% | -0.40% | EXIT | |
| 39 | BTSG | Brightspring Health Services | Stock-Other | 0.39% | +0.17% | +7250.00% | |
| 40 | TWST | Twist Bioscience CORP | Stock-Other | 0.39% | +0.62% | +18562.09% | |
| 41 | BIDU | Baidu Inc - Spon Adr | Stock-Comm Services | 0.28% | +0.35% | +40.75% | |
| 42 | CGON | Cg Oncology Inc | Stock-Other | 0.26% | -0.13% | +8325.00% | |
| 43 | AZN | AstraZeneca PLC | Stock-Healthcare | 0.25% | +0.25% | — | |
| 44 | VNET 2 10-01-27Bond | Vnet Group Inc | Bond | 0.25% | -0.03% | — | |
| 45 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.25% | -0.13% | — | |
| 46 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 0.23% | +0.34% | — | |
| 47 | WELL | Welltower Inc | Stock-Real Estate | 0.23% | -0.23% | -41.69% | |
| 48 | IMVT | Immunovant Inc | Stock-Other | 0.22% | +0.81% | +12783.33% | |
| 49 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.21% | -0.05% | +3.59% | |
| 50 | JNJ | Johnson & Johnson | Stock-Healthcare | 0.21% | +0.27% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ✓ | Spdr S&P 500 Etf Tr Put Option | — | NEW | New buy |
| 2 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 3 | AMZN | Amazon.com Inc | — | NEW | New buy |
| 4 | MSFT | Microsoft CORP | — | NEW | New buy |
| 5 | AON | Aon plc | — | NEW | New buy |
| 6 | BBIO | Bridgebio Pharma Inc | — | NEW | New buy |
| 7 | ✓ | — | NEW | New buy | |
| 8 | PTGX | Protagonist Therapeutics Inc | — | NEW | New buy |
| 9 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 10 | NTRA | Natera Inc | — | NEW | New buy |
| 11 | EXEL | Exelixis Inc | — | NEW | New buy |
| 12 | AVGO | Broadcom Inc | — | NEW | New buy |
| 13 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 14 | SNPS | Synopsys Inc | — | NEW | New buy |
| 15 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 16 | TMO | Thermo Fisher Scientific Inc | — | NEW | New buy |
| 17 | KKR | Kkr & Co Inc | — | NEW | New buy |
| 18 | LNTH | Lantheus Holdings Inc | — | NEW | New buy |
| 19 | WAB | Wabtec CORP | — | NEW | New buy |
| 20 | SCHW | Schwab (charles) CORP | — | NEW | New buy |
| 21 | LQDA | Liquidia CORP | — | NEW | New buy |
| 22 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 23 | GOOG | Alphabet Inc-cl C | — | NEW | New buy |
| 24 | ROIV | Roivant Sciences Ltd. | — | NEW | New buy |
| 25 | V | Visa Inc-class A Shares | — | NEW | New buy |
| 26 | ARMK | Aramark | — | NEW | New buy |
| 27 | BEAM | Beam Therapeutics Inc | — | NEW | New buy |
| 28 | RNAGBP | Avidity Biosciences Inc | — | EXIT | Sold out |
| 29 | DIS | Walt Disney Co/the | — | NEW | New buy |
| 30 | MA | Mastercard Inc - A | — | NEW | New buy |
| 31 | MCK | Mckesson CORP | — | NEW | New buy |
| 32 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 33 | 260 | Centessa Pharmaceuticals-adr | — | NEW | New buy |
| 34 | TNGX | Tango Therapeutics Inc | — | NEW | New buy |
| 35 | GRAL | Grail Inc | — | NEW | New buy |
| 36 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 37 | THC | Tenet Healthcare CORP | — | NEW | New buy |
| 38 | CAH | Cardinal Health Inc | — | NEW | New buy |
| 39 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 40 | DNTH | Dianthus Therapeutics Inc | — | NEW | New buy |
| 41 | BTSG | Brightspring Health Services | — | NEW | New buy |
| 42 | TWST | Twist Bioscience CORP | — | NEW | New buy |
| 43 | BIDU | Baidu Inc - Spon Adr | — | NEW | New buy |
| 44 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 45 | AZN | AstraZeneca PLC | — | NEW | New buy |
| 46 | VNET 2 10-01-27Bond | Vnet Group Inc | — | NEW | New buy |
| 47 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 48 | ACHC | Acadia Healthcare Co Inc | — | NEW | New buy |
| 49 | WELL | Welltower Inc | — | NEW | New buy |
| 50 | IMVT | Immunovant Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Farallon Capital Management, L.l.c. reported a total U.S. public equity portfolio value of $21.7B across 172 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including Spdr S&P 500 Etf Tr Put Option, RVMD, AMZN) accounted for 24.8% of total reported equity market value during Q1 2026.
Top New Position Initiated
Spdr S&P 500 Etf Tr Put Option
市值: $1.5B
Top Position Liquidated / Trimmed
EXK
前期市值: $650.5M
During Q1 2026, Farallon Capital Management, L.l.c.'s top holdings by market value included Spdr S&P 500 Etf Tr Put Option (8.5%)、RVMD (7.5%)、AMZN (5.0%). The largest single position, Spdr S&P 500 Etf Tr Put Option, represented 8.5% of total portfolio value.
In Q1 2026, Farallon Capital Management, L.l.c. made 174 total portfolio adjustments, initiating 172 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.